Covaxin neutralises multiple variants of Coronavirus; ICMR

Bharat Biotech’s COVID-19 vaccine Covaxin neutralises multiple variants of Coronavirus and works in a better way against the double mutant strain, according to Indian Council of Medical Research (ICMR).

“ICMR study shows Covaxin neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well,” the ICMR said in a tweet.

Cavaxin received Emergency Use Authorizations (EUA) for COVID-19 treatment in India and in several countries across the globe with another 60 in the process.

In the tweet, ICMR said “ICMR-National Institute of Virology has successfully isolated and cultured multiple variants of concern of SARS-CoV-2 virus: B.1.1.7 (the UK variant). B.1.1.28 (Brazil variant) and B.1.351 (South Africa variant).”

Further the Institute said “ICMR-NIV has demonstrated the neutralisation potential of Cavaxin against the UK variant and Brazil variant. ICMR-NIV recently has been successful in isolating and culturing the double mutant strain B.1.617 SARS-CoV-2 identified in certain regions of India and several other countries. Covaxin has been found to effectively neutralise the double mutant strain as well.” it said.



Please enter your comment!
Please enter your name here